Search - tctmd.com

Displaying 321 - 340 of 342

Sort: Relevancy | Date

News Conference News TCT 2012

DES: The Year in Review

October 23, 2012

News Conference News TCT 2012

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

October 23, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

Presentation TCT 2012

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Presenter: David Kandzari

October 22, 2012

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

DAPT Trial Update

Presenter: Laura Mauri

October 22, 2012

News Conference News

Stent Thrombosis Linked to Uncovered, Malapposed Stent Struts

November 21, 2011

News Conference News

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

November 09, 2011

News Conference News

ADAPT-DES: Risk of Early Stent Thrombosis in DES Predicted by Platelet Inhibition

November 09, 2011

News Conference News

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

November 08, 2011

News Conference News

Low Event Rates with EES Sustained at 2 Years

November 08, 2011

News Conference News

Bioabsorbable Polymers, Scaffolds Offer Permanent Advantages

November 08, 2011

News Conference News

SAT-TAVI: Data Support TAVR Without Dual Antiplatelet Therapy

November 07, 2011

News Conference News

GHOST: Accurate Medical History May Predict DAPT Adherence in PCI for STEMI

November 06, 2011

News Conference News

Early Discontinuation of DAPT May Increase Risk of Stent Thrombosis

November 06, 2011

Video

» Interview

TCT 2017: Dr. C. Michael Gibson talks with Dr. Elvin Kedhi about DAPT STEMI

May 11, 2018

Video

» Interview

TCT 2016: Dr. C. Michael Gibson talks with Dr. Freek Verheugt about DAPT: The AFib and ACS Overlap

May 11, 2018

Video

» Interview

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy in HBR Patients

November 7, 2021

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Stephan Windecker About Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

September 28, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Ken Kozuma About MODEL U-SES: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Sirolimus-Eluting Stent

September 27, 2019

Advertisement

DES: The Year in Review

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

Several Trials Highlight DES Comparisons

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

DAPT Trial Update

Stent Thrombosis Linked to Uncovered, Malapposed Stent Struts

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

ADAPT-DES: Risk of Early Stent Thrombosis in DES Predicted by Platelet Inhibition

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

Low Event Rates with EES Sustained at 2 Years

Bioabsorbable Polymers, Scaffolds Offer Permanent Advantages

SAT-TAVI: Data Support TAVR Without Dual Antiplatelet Therapy

GHOST: Accurate Medical History May Predict DAPT Adherence in PCI for STEMI

Early Discontinuation of DAPT May Increase Risk of Stent Thrombosis

TCT 2017: Dr. C. Michael Gibson talks with Dr. Elvin Kedhi about DAPT STEMI

TCT 2016: Dr. C. Michael Gibson talks with Dr. Freek Verheugt about DAPT: The AFib and ACS Overlap

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy in HBR Patients

Dr. C. Michael Gibson Talks With Dr. Stephan Windecker About Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

Dr. C. Michael Gibson Talks With Dr. Ken Kozuma About MODEL U-SES: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Sirolimus-Eluting Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content